Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study
published in: BMC Cancer
date of publication: 2016-05-24
language: English
main subject: colorectal cancer, cetuximab, metastatic colon cancer, colorectal carcinoma
Cites articles 29
- 2002-10-01
Date
Title
Article - wd:Q36028658